Clearstead Advisors LLC Increases Stake in Twist Bioscience Corporation $TWST

Posted by Brian Himes on May 31st, 2026

Clearstead Advisors LLC grew its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 29,577.8% during the 4th quarter, HoldingsChannel reports. The firm owned 8,013 shares of the company’s stock after buying an additional 7,986 shares during the period. Clearstead Advisors LLC’s holdings in Twist Bioscience were worth $254,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in Twist Bioscience during the 3rd quarter worth $28,000. Smartleaf Asset Management LLC boosted its stake in Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the last quarter. National Bank of Canada FI acquired a new stake in Twist Bioscience during the 3rd quarter worth $46,000. Finally, Leonteq Securities AG acquired a new stake in Twist Bioscience during the 4th quarter worth $48,000.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00. Following the transaction, the chief financial officer owned 118,694 shares of the company’s stock, valued at approximately $7,121,640. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 8,061 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total value of $526,302.69. Following the transaction, the chief executive officer directly owned 858,887 shares in the company, valued at $56,076,732.23. This trade represents a 0.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,551 shares of company stock valued at $2,566,533 in the last three months. Company insiders own 3.08% of the company’s stock.

Wall Street Analysts Forecast Growth

TWST has been the topic of several recent research reports. Robert W. Baird lifted their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Evercore lifted their target price on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Leerink Partners set a $80.00 target price on shares of Twist Bioscience in a research note on Friday, May 22nd. Finally, Guggenheim boosted their price objective on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $58.00.

Check Out Our Latest Report on Twist Bioscience

Twist Bioscience Stock Performance

NASDAQ TWST opened at $66.87 on Friday. The stock’s fifty day moving average is $54.62 and its two-hundred day moving average is $44.46. The firm has a market capitalization of $4.16 billion, a P/E ratio of -50.28 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $71.04.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted ($0.66) EPS. On average, research analysts anticipate that Twist Bioscience Corporation will post -1.86 earnings per share for the current year.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.